Literature DB >> 6323316

Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.

H E Gilleland, M G Parker, J M Matthews, R D Berg.   

Abstract

The outer membrane protein F (porin) from the PAO1 strain of Pseudomonas aeruginosa was purified by two different methods. One procedure involved separation by column chromatography of proteins extracted from isolated outer membranes, whereas the other involved extraction from gels after slab polyacrylamide gel electrophoresis of proteins extracted from cell envelopes. Both procedures yielded protein F preparations which successfully immunized mice from subsequent challenge with the PAO1 strain. The protein F preparations contained small quantities of lipopolysaccharide (LPS). This level of LPS contamination protected immunized mice from challenge with the homologous LPS serotype strain. However, immunization of mice with protein F preparations from the PAO1 strain also afforded protection against challenge with two different LPS serotype strains. This protective ability was lost when the protein F preparation was treated with papain before use as a vaccine. These observations support the conclusion that protein F has protective ability, which is not due to LPS contamination, when given as a vaccine. After immunization with the protein F preparation, mice showed an increase in antibody titer to the purified protein F preparation by enzyme-linked immunosorbent assay. Mice were protected passively by administration of rabbit antisera raised to the protein F preparation. These results indicate that the protein F preparation elicits a specific humoral antibody response in immunized animals. Our results suggest that purified protein F has potential as an effective vaccine for P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323316      PMCID: PMC263467          DOI: 10.1128/iai.44.1.49-54.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Ultrastructural study of polymyxin-resistant isolates of Pseudomonas aeruginosa.

Authors:  H E Gilleland; R G Murray
Journal:  J Bacteriol       Date:  1976-01       Impact factor: 3.490

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

Review 3.  Burn wounds: microbiology, local host defenses, and current therapy.

Authors:  P Nathan; I A Holder; B G MacMillan
Journal:  CRC Crit Rev Clin Lab Sci       Date:  1973-07

4.  Pseudomonas bacteremia in patients with malignant diseases.

Authors:  J P Whitecar; M Luna; G P Bodey
Journal:  Am J Med Sci       Date:  1970-10       Impact factor: 2.378

5.  Structural investigations on the 2-keto-3-deoxyoctonate region of lipopolysaccharides.

Authors:  W Dröge; V Lehmann; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1970-05-01

6.  Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.

Authors:  W D Zollinger; R E Mandrell; P Altieri; S Berman; J Lowenthal; M S Artenstein
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

7.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

8.  Antibodies against outer membrane proteins in rabbit antisera prepared against Escherichia coli O26 K60.

Authors:  J Dankert; H Hofstra
Journal:  J Gen Microbiol       Date:  1978-02

9.  Protection against infection with Neisseria gonorrhoeae by immunization with outer membrane protein complex and purified pili.

Authors:  T M Buchanan; W A Pearce; G K Schoolnik; R J Arko
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

10.  Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.

Authors:  N Holby; S Olling
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-04
View more
  42 in total

1.  Variation and adaptation of Pseudomonas aeruginosa toxicity to HeLa cells and fibroblasts.

Authors:  H Müller; C Kettelhack; M Kettelhack; H G Sonntag; G Keilich; R Brossmer; J Richards; V Kinzel; E Bäuerlein; H Pech
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

2.  Development of enzyme linked immunosorbent assay (ELISA) to detect antibodies to Pseudomonas aeruginosa cell surface antigens in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood; M S Losowsky
Journal:  J Clin Pathol       Date:  1986-10       Impact factor: 3.411

3.  Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.

Authors:  R E Hancock; L M Mutharia; E C Mouat
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

4.  Bordetella pertussis major outer membrane porin protein forms small, anion-selective channels in lipid bilayer membranes.

Authors:  S K Armstrong; T R Parr; C D Parker; R E Hancock
Journal:  J Bacteriol       Date:  1986-04       Impact factor: 3.490

5.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

6.  Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F.

Authors:  Kathryn J Quigley; Catherine J Reynolds; Amelie Goudet; Eleanor J Raynsford; Ruhena Sergeant; Andrew Quigley; Stefan Worgall; Diana Bilton; Robert Wilson; Michael R Loebinger; Bernard Maillere; Daniel M Altmann; Rosemary J Boyton
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

7.  Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.

Authors:  M Finke; M Duchêne; A Eckhardt; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

8.  Antibody response of swine to outer membrane components of Haemophilus pleuropneumoniae during infection.

Authors:  V J Rapp; R F Ross
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

Review 9.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

10.  Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization.

Authors:  Lucia Peluso; Cristiana de Luca; Silvia Bozza; Antonio Leonardi; Gloria Giovannini; Alfonso Lavorgna; Gaetano De Rosa; Massimo Mascolo; Loredana Ortega De Luna; Maria Rosaria Catania; Luigina Romani; Fabio Rossano
Journal:  BMC Microbiol       Date:  2010-01-13       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.